NCARD Mouse models citations

As of 15/04/2021

  1. Marcq E, Van Audenaerde JRM, De Waele J, Merlin C, Pauwels P, van Meerbeeck JP, Fisher SA, Smits ELJ: The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. Cancers (Basel) 2021, 13(2).
  2. Cook AM, McDonnell A, Millward MJ, Creaney J, Hasani A, McMullen M, Meniawy T, Robinson BWS, Lake RA, Nowak AK: A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Rev Anticancer Ther 2021:1-10.
  3. Cheah HM, Fitzgerald D, Louw A, Creaney J, Lee YCG: Hyaluronic acid in viscous malignant mesothelioma pleural effusion. Respirol Case Rep 2021, 9(1):e00694.
  4. Carey RN, Pfau JC, Fritzler MJ, Creaney J, de Klerk N, A WBM, Franklin P, Sodhi-Berry N, Brims F, Reid A: Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. J Toxicol Environ Health A 2021, 84(11):475-483.
  5. Sneddon S, Rive CM, Ma S, Dick IM, Allcock RJN, Brown SD, Holt RA, Watson M, Leary S, Lee YCG et al: Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology 2020, 9(1):1684713.
  6. Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IM, Robinson BWS, Creaney J: Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. Oncoimmunology 2020, 9(1):1684714.
  7. Louw A, Creaney J, Thomas A, Van Vliet C, Harvey NT, Wood BA, Mesbah Ardakani N: Histologically Diverse BAP1-Deficient Melanocytic Tumors in a Patient With BAP1 Tumor Predisposition Syndrome. Am J Dermatopathol 2020, 42(11):872-875.
  8. Hoon SN, Fyfe K, Peddle-McIntyre CJ, Bowyer S, Hawkins F, Jeffery E, Chih HJ, Creaney J, Nowak A, Brims F: Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol. BMJ Open Respir Res 2020, 7(1).
  9. Fisher SA, Peddle-McIntyre CJ, Burton K, Newton RU, Marcq E, Lake RA, Nowak AK: Voluntary exercise in mesothelioma: effects on tumour growth and treatment response in a murine model. BMC Res Notes 2020, 13(1):435.
  10. Cerciello F, Choi M, Sinicropi-Yao SL, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson BWS, Creaney J, Pass HI et al: Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma. Cancer Epidemiol Biomarkers Prev 2020, 29(10):1973-1982.
  11. Ye L, Ma S, Robinson BW, Creaney J: Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. Expert Rev Respir Med 2019, 13(2):181-192.
  12. Louw A, Badiei A, Creaney J, Chai MS, Lee YCG: Advances in pathological diagnosis of mesothelioma: what pulmonologists should know. Curr Opin Pulm Med 2019, 25(4):354-361.
  13. Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I, Creaney J, Robinson BWS: Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Sci Rep 2019, 9(1):14640.
  14. Birnie KA, Prele CM, Musk AWB, de Klerk N, Lee YCG, Fitzgerald D, Allcock RJN, Thompson PJ, Creaney J, Badrian B et al: MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. Dis Markers 2019, 2019:8628612.
  15. Aston WJ, Hope DE, Cook AM, Boon L, Dick I, Nowak AK, Lake RA, Lesterhuis WJ: Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology 2019, 8(11):e1641390.
  16. Abayasiriwardana KS, Wood MK, Prele CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE: Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. Biochem Biophys Res Commun 2019, 510(2):198-204.
  17. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE et al: Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 2018, 13(11):1655-1667.
  18. Sneddon S, Dick I, Lee YCG, Musk AWB, Patch AM, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS et al: Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer 2018, 119:64-70.
  19. Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J et al: Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. PLoS One 2018, 13(1):e0190264.
  20. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR et al: Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol 2018, 13(9):1269-1283.
  21. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA et al: Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 2018, 8(12):1548-1565.
  22. Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Lesterhuis WJ, Dick IM, Nowak AK et al: Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology 2018, 7(10):e1494111.
  23. Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK et al: Combination immune checkpoint blockade as an effective therapy for mesothelioma. Oncoimmunology 2018, 7(10):e1494111.
  24. Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Lee YCG, Nowak AK et al: Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Res Notes 2018, 11(1):864.
  25. Sneddon S, Patch AM, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J: Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer 2017, 17(1):396.
  26. McDonnell AM, Cook A, Robinson BWS, Lake RA, Nowak AK: Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer 2017, 17(1):417.
  27. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T et al: Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer 2017, 17(1):386.
  28. Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick I, Holt RA et al: Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis 2017, 5(1):16-28.
  29. Creaney J, Robinson BWS: Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment. Chest 2017, 152(1):143-149.
  30. Creaney J, Dick IM, Leon JS, Robinson BW: A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ. Cancer Genomics Proteomics 2017, 14(2):103-117.
  31. Cheah HM, Lansley SM, Varano Della Vergiliana JF, Tan AL, Thomas R, Leong SL, Creaney J, Lee YC: Malignant pleural fluid from mesothelioma has potent biological activities. Respirology 2017, 22(1):192-199.
  32. Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ: A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer 2017, 17(1):684.
  33. Thomas R, Cheah HM, Creaney J, Turlach BA, Lee YC: Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. Chest 2016, 149(6):1494-1500.
  34. Steven A, Fisher SA, Robinson BW: Immunotherapy for lung cancer. Respirology 2016, 21(5):821-833.
  35. Morre DJ, Hostetler B, Taggart DJ, Morre DM, Musk AW, Robinson BW, Creaney J: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin Proteomics 2016, 13:2.
  36. Morre DJ, Hostetler B, Taggart DJ, Morre DM, Musk AW, Robinson BW, Creaney J: Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin Proteomics 2016, 13:3.
  37. Lansley SM, Pedersen B, Robinson C, Searles RG, Sterrett G, van Bruggen I, Lake RA, Mutsaers SE, Prele CM: A Subset of Malignant Mesothelioma Tumors Retain Osteogenic Potential. Sci Rep 2016, 6:36349.
  38. Greening DW, Ji H, Chen M, Robinson BW, Dick IM, Creaney J, Simpson RJ: Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. Sci Rep 2016, 6:32643.
  39. Creaney J, Lee YC: Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies. Ann Am Thorac Soc 2016, 13(7):1003-1004.
  40. Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BW: Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. Biomarkers 2016, 21(6):551-561.
  41. Cook AM, McDonnell AM, Lake RA, Nowak AK: Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology 2016, 5(3):e1066062.
  42. Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK: A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J Thorac Oncol 2016, 11(4):573-582.
  43. Azzopardi M, Thomas R, Muruganandan S, Lam DC, Garske LA, Kwan BC, Rashid Ali MR, Nguyen PT, Yap E, Horwood FC et al: Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. BMJ Open 2016, 6(7):e011480.
  44. Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, Moses EK, Melton PE, de Klerk N et al: Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene 2015, 563(1):103-105.
  45. Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BW, Creaney J, Lake RA: Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer 2015, 15:983.
  46. Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA et al: A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol 2015, 26(12):2483-2490.
  47. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BW: Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol 2015, 45(1):49-59.
  48. Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A et al: Correction: genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One 2015, 10(6):e0130109.
  49. Lim CB, Prele CM, Baltic S, Arthur PG, Creaney J, Watkins DN, Thompson PJ, Mutsaers SE: Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis. Oncotarget 2015, 6(3):1519-1530.
  50. Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A et al: Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Sci Rep 2015, 5:12298.
  51. Leong SL, Zainudin R, Kazan-Allen L, Robinson BW: Asbestos in Asia. Respirology 2015, 20(4):548-555.
  52. Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A et al: Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Diagn Cytopathol 2015, 43(7):563-576.
  53. Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A et al: Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication. Cytopathology 2015, 26(3):142-156.
  54. Hjerpe A, Ascoli V, Bedrossian C, Boon M, Creaney J, Davidson B, Dejmek A, Dobra K, Fassina A, Field A et al: Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Cytojournal 2015, 12:26.
  55. Creaney J, Robinson BW: Author’s response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax 2015, 70(4):374-375.
  56. Creaney J, Ma S, Sneddon SA, Tourigny MR, Dick IM, Leon JS, Khong A, Fisher SA, Lake RA, Lesterhuis WJ et al: Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology 2015, 4(7):e1011492.
  57. Creaney J, Dick IM, Robinson BW: Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med 2015, 21(4):352-356.
  58. Creaney J, Dick IM, Robinson BW: Discovery of new biomarkers for malignant mesothelioma. Curr Pulmonol Rep 2015, 4(1):15-21.
  59. Robinson C, Woo S, Nowak AK, Lake RA: Dietary vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model. Nutr Cancer 2014, 66(3):383-387.
  60. Robinson C, Alfonso H, Woo S, Walsh A, Olsen N, Musk AW, Robinson BW, Nowak AK, Lake RA: Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. PLoS One 2014, 9(8):e103025.
  61. Robinson C, Alfonso H, Woo S, Olsen N, Bill Musk AW, Robinson BW, Nowak AK, Lake RA: Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort. Lung Cancer 2014, 86(1):29-34.
  62. Nelson D, Fisher S, Robinson B: The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res 2014, 2014:789069.
  63. Meniawy TM, Creaney J, Lake RA, Nowak AK: Response to comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’. Br J Cancer 2014, 111(12):2377.
  64. Khong A, Cleaver AL, Fahmi Alatas M, Wylie BC, Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ, Lake RA et al: The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer 2014, 14:969.
  65. Fisher SA, Cleaver A, Lakhiani DD, Khong A, Connor T, Wylie B, Lesterhuis WJ, Robinson BW, Lake RA: Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med 2014, 12:245.
  66. Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW: Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. Dis Markers 2014, 2014:413946.
  67. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ et al: Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014, 69(10):895-902.
  68. Cleaver AL, Bhamidipaty K, Wylie B, Connor T, Robinson C, Robinson BW, Mutsaers SE, Lake RA: Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. Carcinogenesis 2014, 35(2):407-414.
  69. Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA: Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One 2014, 9(9):e107894.
  70. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J: A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013, 45(1):44-48.
  71. Meniawy TM, Creaney J, Lake RA, Nowak AK: Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer 2013, 109(7):1813-1820.
  72. McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA: Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 2013, 62(3):529-539.
  73. Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A et al: Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One 2013, 8(4):e61253.
  74. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA: Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013, 8(4):e61895.
  75. Khong A, Brown MD, Vivian JB, Robinson BW, Currie AJ: Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. J Immunother 2013, 36(7):365-372.
  76. Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW: Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers 2013, 35(2):119-127.
  77. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW: Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 2013, 82(3):491-498.
  78. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW: Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer 2013, 80(1):39-44.
  79. Cadby G, Mukherjee S, Musk AW, Reid A, Garlepp M, Dick I, Robinson C, Hui J, Fiorito G, Guarrera S et al: A genome-wide association study for malignant mesothelioma risk. Lung Cancer 2013, 82(1):1-8.
  80. Brims FJ, Lee YC, Creaney J: The continual search for ideal biomarkers for mesothelioma: the hurdles. J Thorac Dis 2013, 5(3):364-366.
  81. Robinson C, Woo S, Walsh A, Nowak AK, Lake RA: The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer 2012, 64(2):315-322.
  82. Park EK, Yates DH, Creaney J, Thomas PS, Robinson BW, Johnson AR: Association of biomarker levels with severity of asbestos-related diseases. Saf Health Work 2012, 3(1):17-21.
  83. McCoy MJ, Lake RA, van der Most RG, Dick IM, Nowak AK: Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer 2012, 107(7):1107-1115.
  84. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, Armstrong NJ, Vallely MP, Musk AW, Robinson BW et al: Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012, 7(7):1184-1191.
  85. Jackaman C, Lansley S, Allan JE, Robinson BW, Nelson DJ: IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol 2012, 24(6):357-368.
  86. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodriguez Portal JA et al: Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30(13):1541-1549.
  87. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BW, Rusch VW et al: The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011, 12(12):1093-1094; author reply 1094-1095.
  88. Varano Della Vergiliana JF, Lansley S, Tan AL, Creaney J, Lee YC, Stewart GA: Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation. Biol Chem 2011, 392(7):633-642.
  89. Robinson C, Walsh A, Larma I, O’Halloran S, Nowak AK, Lake RA: MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer 2011, 47(1):151-161.
  90. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW: Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma–which is best? Lung Cancer 2011, 74(1):55-60.
  91. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK: Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011, 17(5):1181-1189.
  92. Creaney J, Dick IM, Yeoman D, Wong S, Robinson BW: Auto-antibodies to beta-F1-ATPase and vimentin in malignant mesothelioma. PLoS One 2011, 6(10):e26515.
  93. Boudville N, Paul R, Robinson BW, Creaney J: Mesothelin and kidney function–analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011, 73(3):320-324.
  94. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B et al: The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011, 43(7):668-672.
  95. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH: Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010, 48(6):869-874.
  96. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW: Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010, 19(9):2238-2246.
  97. Creaney J, Musk AW, Robinson BW: Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol 2010, 5(9):1461-1466.
  98. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA: Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2009, 58(8):1219-1228.
  99. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ et al: Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009, 4(9):e6982.
  100. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH: Blood-based early detection of malignant mesothelioma. J Clin Oncol 2009, 27(1):160; author reply 160.
  101. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens 2009, 74(1):1-10.
  102. Jackaman C, Cornwall S, Lew AM, Zhan Y, Robinson BW, Nelson DJ: Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009, 34(1):162-175.
  103. Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG: Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009, 183(12):7898-7908.
  104. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009, 15(4):366-370.
  105. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ: Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009, 182(9):5217-5224.
  106. Sherwood AL, Mutsaers SE, Peeva VK, Robinson C, DeSilva CJ, Swanson NR, Lake RA: Spontaneously immortalized mouse mesothelial cells display characteristics of malignant transformation. Cell Prolif 2008, 41(6):894-908.
  107. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008, 61(2):235-243.
  108. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR: Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008, 178(8):832-837.
  109. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ: Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008, 20(11):1467-1479.
  110. Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol 2008, 180(3):1535-1544.
  111. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008, 3(8):851-857.
  112. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 2008, 98(9):1562-1569.
  113. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007, 62(7):569-576.
  114. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132(4):1239-1246.
  115. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, Tamm M, Black JL, Roth M: ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006, 207(2):540-552.
  116. van der Most RG, Robinson BW, Nelson DJ: Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther 2006, 13(10):897-904.
  117. van der Most RG, Himbeck R, Aarons S, Carter SJ, Larma I, Robinson C, Currie A, Lake RA: Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. J Immunother 2006, 29(2):134-142.
  118. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, Robinson BW, Lake RA: A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 2006, 66(22):10786-10794.
  119. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B: Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 2006, 52(2):189-197.
  120. Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD: A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006, 12(17):5129-5135.
  121. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW: Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006, 1(2):172-174.
  122. van Bruggen I, Nelson DJ, Currie AJ, Jackaman C, Robinson BW: Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother 2005, 28(4):359-367.
  123. Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet 2005, 366(9483):397-408.
  124. Robinson BW, Lake RA: Advances in malignant mesothelioma. N Engl J Med 2005, 353(15):1591-1603.
  125. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I: Soluble mesothelin-related protein–a blood test for mesothelioma. Lung Cancer 2005, 49 Suppl 1:S109-111.
  126. Nelson DJ, Robinson BW, Allan J, van der Most R: Gene therapy of mesothelioma. Expert Opin Biol Ther 2005, 5(8):1039-1049.
  127. Creaney J, Robinson BW: Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005, 19(6):1025-1040, v.
  128. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, Lake RA: Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005, 65(17):7580-7584.
  129. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW: Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004, 173(10):5923-5928.
  130. Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, Robinson BW: Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin Pharmacother 2004, 5(12):2441-2449.
  131. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362(9396):1612-1616.
  132. Nowak AK, Robinson BW, Lake RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003, 63(15):4490-4496.
  133. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003, 170(10):4905-4913.
  134. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ: IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003, 171(10):5051-5063.
  135. Nowak AK, Lake RA, Kindler HL, Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002, 29(1):82-96.
  136. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87(5):491-496.
  137. Robinson BW, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL: Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis–implications for tumor tolerance. Clin Cancer Res 2001, 7(3 Suppl):811s-817s.
  138. Robinson BW, Robinson C, Lake RA: Localised spontaneous regression in mesothelioma — possible immunological mechanism. Lung Cancer 2001, 32(2):197-201.
  139. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B: Tumor progression despite efficient tumor antigen cross-presentation and effective “arming” of tumor antigen-specific CTL. J Immunol 2001, 166(9):5557-5566.
  140. Mukherjee S, Nelson D, Loh S, van Bruggen I, Palmer LJ, Leong C, Garlepp MJ, Robinson BW: The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. Cancer Gene Ther 2001, 8(8):580-588.
  141. McLaren BR, Whitaker D, Robinson BW, Lake RA: Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma. Cancer Chemother Pharmacol 2001, 48(1):1-8.
  142. Creaney J, McLaren BM, Stevenson S, Musk AW, de Klerk N, Robinson BW, Lake RA: p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 2001, 84(1):52-56.
  143. Robinson C, Callow M, Stevenson S, Scott B, Robinson BW, Lake RA: Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 2000, 22(5):550-556.
  144. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D et al: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000, 7(5):663-670.
  145. McLaren BR, Robinson BW, Lake RA: New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. Cancer Chemother Pharmacol 2000, 45(6):502-508.
  146. McLaren BR, Haenel T, Stevenson S, Mukherjee S, Robinson BW, Lake RA: Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. Aust N Z J Med 2000, 30(4):450-456.
  147. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B: Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000, 165(11):6047-6055.
  148. Pass HI, Robinson BW, Testa JR, Carbone M: Emerging translational therapies for mesothelioma. Chest 1999, 116(6 Suppl):455S-460S.
  149. Marzo AL, Lake RA, Robinson BW, Scott B: T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999, 59(5):1071-1079.
  150. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW, Scott B: Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999, 162(10):5838-5845.
  151. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B: Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am J Respir Cell Mol Biol 1999, 21(3):347-356.
  152. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17(1):25-30.
  153. Robinson C, Robinson BW, Lake RA: Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 1998, 20(3):175-184.
  154. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M et al: Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998, 21(3):211-217.
  155. Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL, Drury P, Shilkin K, Robinson BW: Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 1998, 21(5):389-398.
  156. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BW: Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 1998, 19(5):738-746.
  157. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B: Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997, 57(15):3200-3207.
  158. Leong CC, Marley JV, Loh S, Robinson BW, Garlepp MJ: The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol Cell Biol 1997, 75(4):356-359.
  159. Leong CC, Marley JV, Loh S, Milech N, Robinson BW, Garlepp MJ: Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. Int J Cancer 1997, 71(3):476-482.
  160. Jarnicki AG, Fitzpatrick DR, Robinson BW, Bielefeldt-Ohmann H: Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 1996, 103(1):1-9.
  161. Upham JW, Garlepp MJ, Musk AW, Robinson BW: Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995, 50(8):887-893.
  162. Fitzpatrick DR, Manning LS, Musk AW, Robinson BW, Bielefeldt-Ohmann H: Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 1995, 21(3):273-288.
  163. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BW, Fitzpatrick DR: Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 1995, 40(4):241-250.
  164. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Musk AW, Robinson BW: Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995, 15(3):213-223.
  165. Leong CC, Robinson BW, Garlepp MJ: Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int J Cancer 1994, 59(2):212-216.
  166. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW: Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994, 11(1):29-44.
  167. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BW: Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994, 39(6):347-359.
  168. Mavaddat N, Robinson BW, Rose AH, Manning LS, Garlepp MJ: An analysis of the relationship between gamma delta T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity. Immunol Cell Biol 1993, 71 ( Pt 1):27-37.
  169. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW: Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992, 52(6):881-886.
  170. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BW: Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991, 47(2):285-290.